Trial · NCT00540436
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 12 | GSK1325760A | 33.49 | Standard Deviation 43.236 | Meters | |
| Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24/Withdrawal | GSK1325760A | 46.82 | Standard Deviation 52.705 | Meters | |
| Mean Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24 | GSK1325760A | Week 12 | -0.60 | Standard Deviation 2.157 | Points on a scale |
| Mean Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24 | GSK1325760A | Week 24 | -0.69 | Standard Deviation 1.904 | Points on a scale |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | Improved at Week 12 | 9 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | No change at Week 12 | 16 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | Deteriorated at Week 12 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | Improved at Week 24 | 10 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | No change at Week 24 | 14 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | GSK1325760A | Deteriorated at Week 24 | 1 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event | GSK1325760A | Death | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event | GSK1325760A | Lung transplantation | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event | GSK1325760A | Hospitalization for PAH treatment | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event | GSK1325760A | Atrial Septostomy | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event | GSK1325760A | Study discontinuation (additional medication) | 1 | Participants | |
| Mean Change From Baseline in Mean Pulmonary Atery Pressure (mPAP) and Mean Right Atrial Pressure (mRAP) at Weeks 12 and 24 | GSK1325760A | mPAP (mmHg) at Week 12, n=21 | -6.29 | Standard Deviation 11.201 | mmHg |
| Mean Change From Baseline in Mean Pulmonary Atery Pressure (mPAP) and Mean Right Atrial Pressure (mRAP) at Weeks 12 and 24 | GSK1325760A | mRAP (mmHg) at Week 12, n=21 | -1.12 | Standard Deviation 3.761 | mmHg |
| Mean Change From Baseline in Mean Pulmonary Atery Pressure (mPAP) and Mean Right Atrial Pressure (mRAP) at Weeks 12 and 24 | GSK1325760A | mPAP (mmHg) at Week 24, n=16 | -8.69 | Standard Deviation 13.903 | mmHg |
| Mean Change From Baseline in Mean Pulmonary Atery Pressure (mPAP) and Mean Right Atrial Pressure (mRAP) at Weeks 12 and 24 | GSK1325760A | mRAP (mmHg) at Week 24, n=16 | -0.69 | Standard Deviation 3.683 | mmHg |
| Mean Change From Baseline in Cardiac Index (CI) at Weeks 12 and 24 | GSK1325760A | Week 12, n=21 | 0.623 | Standard Deviation 0.5980 | L/min/m2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00540436/results